Company profile for Caliway Biopharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Founded in 2012, Caliway focuses on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, targeting areas with unmet medical needs and a growing market worth more than $10 billion to expand their market opportunity. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and reduce subcutaneous fat effectively without ...
Founded in 2012, Caliway focuses on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, targeting areas with unmet medical needs and a growing market worth more than $10 billion to expand their market opportunity. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and reduce subcutaneous fat effectively without causing tissue necrosis or prominent side effects. The results of the CBL-514 clinical trial demonstrated its promising potential in competing in the fat reduction market that is worth more than USD$100 billion.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Taiwan
Address
Address
32F.-9, No.99, Sec.1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221
Telephone
Telephone
+886-2-2697-1355
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/caliway-biopharmaceuticals-presents-preclinical-research-supporting-a-multi-mechanism-approach-to-weight-management-at-tmaso-2025-302643052.html

PR NEWSWIRE
16 Dec 2025

https://www.prnewswire.com/news-releases/caliway-met-dual-milestones-with-msci-global-standard-index-inclusion-and-health-canada-has-approved-the-phase-3-supreme-01-study-302527535.html

PR NEWSWIRE
12 Aug 2025

https://www.prnewswire.com/news-releases/caliway-announces-fda-clearance-of-ind-application-for-cbl-514-to-proceed-with-supreme-01-the-first-global-pivotal-phase-3-study-for-reducing-abdominal-subcutaneous-fat-302514808.html

PR NEWSWIRE
28 Jul 2025

https://www.prnewswire.com/news-releases/caliway-to-present-first-preclinical-data-on-cbl-514-for-glp-1-weight-rebound-management-at-bio-2025-302477476.html

PR NEWSWIRE
10 Jun 2025

https://www.prnewswire.com/news-releases/caliway-announces-successful-eop2-meeting-with-the-fda-for-cbl-514-in-reduction-of-abdominal-subcutaneous-fat-302454923.html

PR NEWSWIRE
14 May 2025

https://www.prnewswire.com/news-releases/caliway-selected-to-present-cbl-514-phase-2-study-results-for-dercums-disease-at-world-orphan-drug-congress-usa-2025-302431424.html

PR NEWSWIRE
17 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty